GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus Oncology Inc (NAS:CHRS) » Definitions » Quick Ratio

CHRS (Coherus Oncology) Quick Ratio : 1.20 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Coherus Oncology Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Coherus Oncology's quick ratio for the quarter that ended in Mar. 2025 was 1.20.

Coherus Oncology has a quick ratio of 1.20. It generally indicates good short-term financial strength.

The historical rank and industry rank for Coherus Oncology's Quick Ratio or its related term are showing as below:

CHRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.96   Med: 2.88   Max: 7.78
Current: 1.2

During the past 13 years, Coherus Oncology's highest Quick Ratio was 7.78. The lowest was 0.96. And the median was 2.88.

CHRS's Quick Ratio is ranked worse than
75.59% of 1495 companies
in the Biotechnology industry
Industry Median: 3.38 vs CHRS: 1.20

Coherus Oncology Quick Ratio Historical Data

The historical data trend for Coherus Oncology's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus Oncology Quick Ratio Chart

Coherus Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.97 3.42 2.47 1.24 0.96

Coherus Oncology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 1.07 1.09 0.96 1.20

Competitive Comparison of Coherus Oncology's Quick Ratio

For the Biotechnology subindustry, Coherus Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus Oncology's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Quick Ratio falls into.


;
;

Coherus Oncology Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Coherus Oncology's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Quick Ratio (A: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(341.583-70.094)/282.981
=0.96

Coherus Oncology's Quick Ratio for the quarter that ended in Mar. 2025 is calculated as

Quick Ratio (Q: Mar. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(310.175-3.518)/255.042
=1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coherus Oncology  (NAS:CHRS) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Coherus Oncology Quick Ratio Related Terms

Thank you for viewing the detailed overview of Coherus Oncology's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus Oncology Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Executives
Mats Wahlstrom director 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025

Coherus Oncology Headlines

From GuruFocus